All News
RheumNow Podcast – The Future of JAKs (6.5.20)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
EULAR and ACR COVID19 Guidelines: Similarities Provide Reassurance
In difficult times, it's reassuring to reflect on the similarities that bring us together. In the case of the EULAR and ACR COVID19 guidelines as discussed at #EULAR2020 by Drs.
Read Article
Preventing COVID - Masks, Meters and Eyewear
A Lancet systematic review and meta-analysis provides the basis for physical distancing and the value of making as measures to prevent infection with coronavirus 2 (SARS-CoV-2) or COVID-19.
The analysis included 172 observational studies, no randomised controlled trials and 44 relevant comparative studies involving 25 697 patients.
Interesting observation: obese patients seem to respond better to etanercept than to mAb TNFi @RheumNow https://t.co/WrjwE4jUNI
k dao KDAO2011 ( View Tweet)
#eular2020 #op0226 humanized antiIL17a ab NETAKIMAB (NTK)for PsA Ph3 PATERA trial: pts who failed cDMARDs and/or 1TNFi experience significantly ⬆️ ACR20/50/70 &PsACR response vs PBO. DAPSA remission 36.08% NTK vs 13.4%PBO. AEs: lympho&neutropenia, ⬆️cholesterol,⬆️bili @RheumNow https://t.co/xqc9Z1T9O0
Olga Petryna DrPetryna ( View Tweet)
I have been impressed with the quality and content of the presentations at #EULAR2020! Here I am trying to navigate the meeting in between telehealth visits at my command center! @RheumNow https://t.co/aGDAr8PPkA
k dao KDAO2011 ( View Tweet)
Big one from plenary, new option in ANCA-associated vasculitis:
avacopan (anti-C5a) vs prednisolone in patients receiving CYC/RTX: non-inf at 26w, superior at 52w in the phase III ADVOCATE trial with reduction in steroid toxicity
Merkel, Jayne et al OP0011 #EULAR2020 @RheumNow
David Liew drdavidliew ( View Tweet)
#eular2020 #op0302 Ianalumab (VAY736) dual action BAFFreceptor inhibitor/B cell depletion meets primary end point in p2b for pSS: EESDAI⬇️1.92 pts over PBO at wk24. Dis not meet 2ry endpoint ESSPRI&FACIT-F. Good side effect profile w/mild inj site reactions mostly @RheumNow https://t.co/9qsfUNho9h
Olga Petryna DrPetryna ( View Tweet)
You might think that steroid exposure in PMR patients wouldn't lead to new comorbidities.
These data beg to differ. New steroid-related comorbidities ++ across domains vs matched controls in real-world US claims data.
We need steroid-sparing in PMR.
OP0271 #EULAR2020 @RheumNow https://t.co/mSzWcJSpfV
David Liew drdavidliew ( View Tweet)
New #therapeutic strategies in #SLE management
#EULAR2020 https://t.co/dhvTKd4EGB
dr hanady manasfi hanadymanasfi ( View Tweet)
Does TCZ actually fix GCA?
@nihrheumatology cohort w serial PET/CT q6m:
FDG uptake (PETVAS) reduces longitudinally over 2y but does not normalise, w rebound on TCZ cessation
Ongoing reductions in year 2? GCA doesn't sleep.
@KQuinnRheum @petercgrayson OP0144 #EULAR2020 @RheumNow https://t.co/aczQbONcNc
David Liew drdavidliew ( View Tweet)
Our study shows that HCQ retinopathy virtually never occurs in first 5 yrs, SLE has more risk than other diseases such as RA and chloroquine has a far higher risk of retinal toxicity OP0333 #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/ZzRy3po4yw
Janet Pope Janetbirdope ( View Tweet)
Serum calprotectin as a biomarker in ANCA-associated vasculitis is enticing, and not just during induction:
during maintenance following remission, it might predict relapse and renal decline independently of disease characteristics
MAINRITSAN data OP0031 #EULAR2020 @RheumNow https://t.co/ItI0BPGrUX
David Liew drdavidliew ( View Tweet)
#EULAR2020 OP0167 Results are finally in!!
MMF can be safely w/drawn in quiescent SLE: prospect RCT (nonblinded) 102 pts. MMF tapered over 12 weeks, f/u 60 weeks; no sig diff for flares in pts who stopped MMF vs. maintained; pts who cont MMF had ⬆️ minor infections. @rheumnow https://t.co/bOnuEBLis9
k dao KDAO2011 ( View Tweet)
So #EULAR2020 was meant to be in Germany, and I was meant to go. I am currently not in Germany.
Germany can come to me!
Just getting into the #EULAR2020goesvirtual spirit @RheumNow https://t.co/RxeTwunR0K
David Liew drdavidliew ( View Tweet)
When starting IV Pegloticase in #Gout, Do you start a DMARD too? #EULAR2020
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast is up! The Future of JAKs. Watch it here>> https://t.co/Ot483P99RB or listen to the Podcast on iTunes>>https://t.co/FHJv01AAbC or on SoundCloud>>https://t.co/1ImZzhb0mS
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib shown to be effective (vs Placebo) in 225 Polyarticular JIA (included some ERA & PsA). with less flares (29 vs 53%) and higher JCR30 responses (71 vs 47%) @6mos #EULAR2020 #OP0281 https://t.co/3BnZeB4ROr https://t.co/4pTLbTtBdN
Links:
Dr. John Cush RheumNow ( View Tweet)
CDC guidelines for Rx of Latent Tuberculosis; Preferred: A) 3 months of once-weekly INH plus rifapentine (3HP); B) 4 months of daily rifampin (4R); C) 3 months of daily INH plus rifampin (3HR) - Shorter, safer, effective with higher completion rates. https://t.co/a2iZczFTP2
Links:
Dr. John Cush RheumNow ( View Tweet)
Lancet has issued an almost retraction - an "Expression of Concern" alerting readers that many have voiced scientific concerns about the Lancet HCQ/CQ paper w/ more deaths. MORE DEATHS COULD HAVE BEEN FROM THE DRUGS OR THE DRUGS BEING USED IN SICKER PTS https://t.co/saoE32qpuF
Links:
Dr. John Cush RheumNow ( View Tweet)
